Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses new guidelines for the treatment of patients with metastatic breast cancer. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Researchers at UC San Francisco are leading the way in identifying new pathways to treating many types of cancer. You can be a part of this movement by contributing directly to the UCSF Helen Diller Family Comprehensive Cancer Center. Give today at http://proj.at/1anxbig
Hormone therapy is a standard treatment for both early-stage and metastatic breast cancer. New studies show that extending the duration of treatment in post-menopausal women beyond the standard five years may reduce cancer recurrence and improve survival.
Hope S. Rugo, MD
Clinical Professor of Medicine; Director, Breast Oncology Clinical Trials Program
UCSF Helen Diller Family Comprehensive Cancer Center